Higher Percentage of FISH-determined Monosomy 3 and 8q Amplification in Uveal Melanoma Cells Relate to Poor Patient Prognosis
Overview
Authors
Affiliations
Purpose: To investigate the relation between patient survival and incrementally increasing percentages of fluorescence in situ hybridization-determined complete loss of chromosome 3 (monosomy 3) and gain of chromosome 8q in primary uveal melanoma cells.
Methods: Clinicopathological factors were related to disease-free survival. Fluorescence in situ hybridization was performed using probes on chromosomes 1, 3, 6, and 8. The percentages of UM cells with monosomy 3 or chromosome 8q gain were classified in groups with incrementally increasing percentages and related to disease-free survival. Correlations between clinical factors and cytogenetic aberrations were also analyzed.
Results: Two-hundred twenty choroidal and ciliary body melanomas were analyzed. The following proved to be significant predictors of survival in univariate analysis: older patient age (P = 0.003); large tumor diameter (P < 0.001); mixed cell type (P = 0.001); presence of closed microvascular loops (P < 0.001); loss of chromosome 1p (P = 0.006); monosomy 3 (P < 0.001); gain of 6p (P < 0.001); and gain of chromosome 8q (P < 0.001). Multivariate Cox analysis displayed monosomy 3 (Hazard ratio [HR] 2.83, P = 0.002) and gain of chromosome 8q (HR 3.13, P = 0.002) as the most important independent prognostic factors of poor survival, followed by older patient age (HR 1.02, P = 0.017). Increasing percentages of monosomy 3 and gain of chromosome 8q in tumor cells showed a correlation with worse prognosis (Log-rank test 49.9 and 40.4, both P < 0.001) and increased number of additional copies of 8q correlated with shorter disease-free interval (Log-rank test 45.7, P < 0.001).
Conclusions: A high percentage monosomy 3 and chromosome 8q gain in primary UM cells showed a strong relation with poor disease-free survival compared with low percentage aberrations.
van den Bosch Q, Kilic E, Brosens E Invest Ophthalmol Vis Sci. 2024; 65(10):26.
PMID: 39163035 PMC: 11346061. DOI: 10.1167/iovs.65.10.26.
Lalonde E, Li D, Ewens K, Shields C, Ganguly A Cancers (Basel). 2024; 16(15).
PMID: 39123378 PMC: 11312132. DOI: 10.3390/cancers16152650.
Pathological and Molecular Diagnosis of Uveal Melanoma.
Pasarica M, Curca P, Dragosloveanu C, Grigorescu A, Nisipasu C Diagnostics (Basel). 2024; 14(9).
PMID: 38732371 PMC: 11083017. DOI: 10.3390/diagnostics14090958.
Immunoembolization for the Treatment of Uveal Melanoma Hepatic Metastases.
Gonsalves C Semin Intervent Radiol. 2024; 41(1):20-26.
PMID: 38495266 PMC: 10940043. DOI: 10.1055/s-0043-1777712.
Nguyen J, Drabarek W, Vaarwater J, Yavuzyigitoglu S, Verdijk R, Paridaens D Ophthalmol Sci. 2024; 4(2):100413.
PMID: 38187129 PMC: 10767501. DOI: 10.1016/j.xops.2023.100413.